Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study

NCT ID: NCT01914159


Title
Purpose
The Ranibizumab in Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration (RIP) Study is a prospective, multicenter, uncontrolled, interventional phase 2 clinical trial that investigates the effect of fixed monthly intravitreal injections of ranibizumab (Lucentis, Novartis Pharma, Germany) on visual acuity and retinal morphology over a study period of 12 months in 30 patients.
Details
Conditions
Age Related Macular Degeneration
Keywords
Source
University Hospital, Bonn
Sponsors
University Hospital, Bonn
Status
Completed
Acronym
RIP
Last Updated
11 May 2016
URL
Official Link
Locations
Germany